通过拉帕提尼布破坏DDB2-DNA相互作用提高了化疗敏感性
Shih-Chao Hsu1,2, Yu-Hao He1,3,4, Yun-Ju Chen5,6
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 404333, Taiwan.
损坏的DNA结合蛋白2 (DDB2) 通过帮助DNA修复来驱动化学抵抗. 药物拉帕提尼布破坏DDB2,使癌细胞对化疗重新敏感,并改善生存结果.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药物发现 药物发现
背景情况:
- 化学抵抗是癌症治疗的一个主要挑战.
- 损坏的DNA结合蛋白2 (DDB2) 通过DNA修复和亡抑制参与化学抵抗.
- DDB2的升高与几种癌症的预后不佳相关.
研究的目的:
- 为了研究DDB2在化学抵抗中的作用.
- 确定针对DDB的新型治疗策略2.2.
- 评估拉帕蒂尼布作为DDB2抑制剂和化学敏感剂.
主要方法:
- 基于结构的虚拟查和分子动力学模拟以识别DDB2抑制剂.
- 细胞热转移测定和染色质分离以确认药物标相互作用.
- 使用癌细胞系和患者衍生器官的体外和体外研究来评估药物的疗效.
主要成果:
- 乳腺癌,肝癌,胆管癌和肺癌中DDB2水平升高与患者生存率降低相关.
- 拉帕提尼布被确定为DDB2/DNA复合物的破坏者,减少DDB2染色体协会并促进其降解.
- 与拉帕提尼布和多克索鲁比辛的同时治疗在癌症模型中显示出协同性细胞毒性.
结论:
- DDB2是化学抵抗的关键媒介.
- 拉帕提尼布通过准DNA修复机制,表现出一种新的作用机制.
- 将拉帕蒂尼布重新用作一种化学敏感剂,为克服化学抵抗提供了一种新的策略.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Abnormal Proliferation
Drugs that Destabilize Microtubules
